AUNA's Post-Q4 Rally Masks Persistent Mexico and Leverage Risks

What happened

AUNA's stock rallied after Q4 earnings, buoyed by reported Peru growth and Mexico recovery signals. However, the DeepValue report reveals that Mexico's financials remain weak, with a 12% YoY revenue decline and 29% EBITDA drop in 3Q25. Leverage is elevated at ~3.6x Net Debt/EBITDA, and the $500M Mexico investment plan risks equity dilution if funded poorly. Critical milestones include resolving Doctors Hospital IT issues and achieving YoY Mexico revenue growth by 2Q26 without dilutive financing. Therefore, the rally appears premature without concrete evidence of operational normalization.

Implication

The Q4 performance offers tentative signs of improvement, but investors must confirm it translates into sustained YoY growth in Mexico's revenue and EBITDA. High leverage at ~3.6x Net Debt/EBITDA limits financial flexibility and increases vulnerability to operational setbacks. Equity dilution from the $500M Mexico plan could significantly erode per-share value if executed at depressed prices. Key monitoring points include Mexico utilization rates and financing announcements in the coming quarters. Until these risks are mitigated, adhering to a wait-and-see stance with entry near $4.60, as per DeepValue, is prudent.

Thesis delta

The article's optimism based on Q4 results does not materially alter the DeepValue thesis, which remains contingent on Mexico's financial inflection and leverage improvement. If Q4 data confirms YoY recovery in Mexico, it could shift probabilities toward the base or bull scenarios, but such evidence is not yet provided in the report. Thus, the thesis stands: wait for concrete proof of operational normalization before committing capital.